Last updated: February 19, 2026
Bortezomib, marketed primarily as Velcade, is a proteasome inhibitor used in cancer treatment, specifically multiple myeloma and mantle cell lymphoma. It is produced by several pharmaceutical companies worldwide, with major suppliers including the originator brand and generic manufacturers.
Major Suppliers of Bortezomib
Originator and Patented Suppliers
| Supplier |
Product Name |
Market Presence |
Manufacturing Capacity |
Approval Milestones |
Notes |
| Millennium/Takeda |
Velcade |
Globally licensed |
Large-scale manufacturing |
FDA approval 2003, EMA 2004 |
First-in-class proteasome inhibitor; leading market share |
| Javelin Pharmaceuticals |
Bortezomib |
Limited |
Small to medium |
No recent approval updates |
Focus on niche or regional markets |
Generic Manufacturers
| Supplier |
Product Name |
Market Presence |
Manufacturing Capacity |
Regulatory Approval |
Notes |
| Teva Pharmaceuticals |
Generic Bortezomib |
Global, especially US, Europe |
Large-scale |
Pending or obtained approval in multiple regions |
First major generic, launched post-patent expiry (2012) |
| Intas Pharmaceuticals |
Bortezomib |
India, emerging markets |
Moderate |
Approved in India, dossier filed elsewhere |
Competes at lower price points |
| Sagent Pharmaceuticals |
Sagent Bortezomib |
US, global markets |
Moderate |
Approved by FDA in 2014 |
Focus on sterile injectables |
| Dr. Reddy’s Laboratories |
Bortezomib |
India, Latin America |
Moderate |
Approved in India and select markets |
Focus on regional expansion |
| Sun Pharmaceutical Industries |
Bortezomib |
India, global markets |
Large-scale |
Regulatory submissions ongoing |
Increasing global footprint |
Supply Chain Considerations
- Manufacturing capacity varies significantly; major originators operate facilities in North America, Europe, and Asia to meet global demand.
- Regulatory approvals for generics differ by region; most have approvals in India, with some pursuing or holding approvals in the US and European Union.
- Pricing strategies: Original branded Velcade tends to be high-cost, restricts access in some markets; generics are priced lower, expanding access.
Key Market Dynamics
- Patent expiration for Velcade occurred in 2012 in the US, prompting the growth of generic versions.
- Several generic manufacturers have obtained approvals in key markets, increasing global supply options.
- Supply consolidation is limited; fragmentation exists among regional generic providers.
Market Trends and Future Outlook
- Increased manufacturing capacity from generics is expected to continue, driven by rising demand and patent expiration.
- Regulatory pathways for biosimilar and biosimilar-like versions of proteasome inhibitors are under development but currently limited.
- Supply chain disruptions, such as those caused by global events, could influence pricing and availability.
Regulatory and Patent Landscape
- The original patent for Velcade expired in most major markets by 2012.
- Regulatory approval of generics requires demonstrating bioequivalence and manufacturing quality compliance.
- Current patent filings focus on next-generation proteasome inhibitors rather than bortezomib itself, indicating limited dual patent protection.
Key Takeaways
- The main supplier remains Takeda with its Velcade brand, complemented by multiple generic manufacturers.
- Patent expirations have expanded supply options via generics, reducing prices and increasing access.
- Manufacturing capacity and regulatory approvals vary significantly across regions.
- Supply chain risks exist due to regional disparities and ongoing regulatory processes.
- The future of supply hinges on regulatory approvals, capacity expansion, and potential biosimilar development.
FAQs
1. Who are the leading manufacturers of generic bortezomib?
Teva Pharmaceuticals is the largest manufacturer globally, with approvals in the US, EU, and other markets. Other notable manufacturers include Intas, Sun Pharma, and Dr. Reddy’s.
2. What are the regulatory hurdles for generic bortezomib?
Manufacturers must demonstrate bioequivalence, consistent manufacturing practices, and obtain regional regulatory approval, often involving complex stability and bioavailability studies.
3. How does patent expiry affect the market supply of bortezomib?
Patent expiry in 2012 led to increased competition from generics, lowering prices and expanding regional supply options.
4. Are biosimilar versions of bortezomib in development?
Biosimilars are not yet approved; development is ongoing but limited by the complexity of proteasome inhibitor biosimilars.
5. What risks could impact future bortezomib supply?
Manufacturing disruptions, regional regulatory changes, and geopolitical factors could restrict supply or alter pricing dynamics.
Sources:
[1] Drug patent and approval data, FDA and EMA oficial websites.
[2] Market analysis reports from IQVIA, 2022.
[3] Company disclosures and press releases, 2022–2023.
[4] U.S. Patent and Trademark Office records, 2012–2023.
